News | May 03, 2023
Astec LifeSciences FY23 PAT declines to Rs. 25.6 Cr
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
The consolidated EBITDA stood at Rs. 89.3 crore in FY23 as compared to Rs. 164.5 crore in the same period last year
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Apremilast Tablets, 10 mg, 20 mg, and 30 mg is a generic equivalent of reference listed drug (RLD) OTEZLA of Celgene.
FDA’s NME approvals declined substantially in 2022, causing overall New Drug Application (NDA) approvals to drop
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
This loan is in addition to earlier announced CAD 25 million loan committed by the Province of Quebec
He is a Chartered Accountant with more than 19 years of extensive experience
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
The investment will enable the company to enter European markets as well as enhance margins in current markets
Subscribe To Our Newsletter & Stay Updated
